Author: Paul Tardner Date published: 01/05/2023
Originally published at: IJEST Pull test PDF: View PDF
Abstract
Attention–Deficit/Hyperactivity Disorder (ADHD) is a prevalent neurodevelopmental
disorder, affecting individuals of all ages. Despite the range of available treatments, there is
still a need for further research and development of additional treatment options. Guanfacine,
a selective α2A–adrenergic receptor agonist, has recently garnered attention as a potential
alternative or adjunct therapy for ADHD. This literature review examines the existing
research on guanfacine’s efficacy and safety, comparing it to other available ADHD
treatments, and exploring its potential role in treating ADHD.
Keywords: guanfacine, ADHD, nootropics
Works Cited
1. American Psychiatric Association. (2013). Diagnostic and
statistical manual of mental disorders (5th ed.). Arlington,
VA: American Psychiatric Publishing.
2. Arnsten, A. F. (2011). Catecholamine influences on
dorsolateral prefrontal cortical networks. Biological
Psychiatry, 69(12), e89–e99.
3. Barkley, R. A. (1997). Behavioral inhibition, sustained
attention, and executive functions: Constructing a
unifying theory of ADHD. Psychological Bulletin,
121(1), 65–94.
4. Berridge, C. W., Devilbiss, D. M., Andrzejewski, M. E.,
Arnsten, A. F., Kelley, A. E., Schmeichel, B., … &
Spencer, R. C. (2012). Methylphenidate preferentially
increases catecholamine neurotransmission within the
prefrontal cortex at low doses that enhance cognitive
function. Biological Psychiatry, 72(12), 1015–1023.
5. Biederman, J., Melmed, R. D., Patel, A., McBurnett, K.,
Konow, J., Lyne, A., … & Glicklich, L. (2008). A
randomized, double–blind, placebo–controlled study of
guanfacine extended release in children and adolescents
with attention–deficit/hyperactivity disorder. Pediatrics,
121(1), e73–e84.
6. Coghill, D., Banaschewski, T., Lecendreux, M., Soutullo,
C., Johnson, M., Zuddas, A., … & Squires, L. (2014).
European, randomized, phase 3 study of
lisdexamfetamine dimesylate in children and adolescents
with attention–deficit/hyperactivity disorder. European
Neuropsychopharmacology, 24(10), 1661–1672.
7. Connor, D. F., Findling, R. L., Kollins, S. H., Sallee, F.
R., López, F. A., Lyne, A., … & Steeber, J. (2010). Effects
of guanfacine extended release on oppositional symptoms
in children aged 6–12 years with attention–deficit
hyperactivity disorder and oppositional symptoms: a
randomized, double–blind, placebo–controlled trial. CNS
Drugs, 24(9), 755–768.
8. Faraone, S. V., Glatt, S. J., & Bukstein, O. G. (2013). A
practical clinical protocol for evaluating the efficacy and
safety of adding guanfacine extended release to
psychostimulant therapy for treating ADHD in
adolescents. Journal of Attention Disorders, 17(4), 273–
280.
9. Hervas, A., Huss, M., Johnson, M., McNicholas, F., van
Stralen, J., Sreckovic, S., … & Robertson, B. (2014).
Efficacy and safety of extended–release guanfacine
hydrochloride in children and adolescents with attention–
deficit/hyperactivity disorder: a randomized, controlled,
phase III trial. European Neuropsychopharmacology,
24(12), 1861–1872.
10. Polanczyk, G., de Lima, M. S., Horta, B. L., Biederman,
J., & Rohde, L. A. (2007). The worldwide prevalence of
ADHD: A systematic review and metaregression analysis.
American Journal of Psychiatry, 164(6), 942–948.
11. Simon, V., Czobor, P., Bálint, S., Mészáros, Á., & Bitter,
I. (2009). Prevalence and correlates of adult attention–
deficit hyperactivity disorder: Meta–analysis. British
Journal of Psychiatry, 194(3), 204–211.
12. Taylor, F. B., Watson, J. T., & Feller, C. P. (1982).
Guanfacine use in children with attention deficit
hyperactivity disorder. American Journal of Psychiatry,
139(9), 1128–1131.
13. Volkow, N. D., Swanson, J. M., Wigal, T., Fowler, J. S.,
Telang, F., Wang, G. J., … & Wong, C. (2007).
Therapeutic doses of oral methylphenidate significantly
increase extracellular dopamine in the human brain.
Journal of Neuroscience, 27(3), 527–534.
14. Wilens, T. E., Bukstein, O., Brams, M., Cutler, A. J.,
Childress, A., Rugino, T., … & Youcha, S. (2012). A
controlled trial of extended–release guanfacine and
psychostimulants for attention–deficit/hyperactivity
disorder. Journal of the American Academy of Child &
Adolescent Psychiatry, 51(1), 74–85.
15. Wolraich, M. L., Hagan, J. F., Allan, C., Chan, E.,
Davison, D., Earls, M., … & Holbrook, J. R. (2019).
Clinical practice guideline for the diagnosis, evaluation,
and treatment of attention–deficit/hyperactivity disorder in
children and adolescents. Pediatrics, 144(4), e20192528.